Based on technology at University of Pennsylvania, iEcure has launched to commercialise gene therapies initially for liver disorders and an option to license more assets.
iEcure, a US-based mutation-agnostic in vivo gene-editing company, has been spun out of University of Pennsylvania with $50m in series A funding co-led by Versant Ventures and OrbiMed Advisors.
The spinout will focus on cures for devastating conditions with a high unmet need, and its approach relies on an endonuclease-based gene-editing technology delivered via adeno-associated virus.
It builds on research spearheaded by James Wilson, director of the Gene Therapy Program (GTP), the Rose H Weiss professor and director…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.